We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Exiqon Secures Funding to Accelerate Growth
News

Exiqon Secures Funding to Accelerate Growth

Exiqon Secures Funding to Accelerate Growth
News

Exiqon Secures Funding to Accelerate Growth

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Exiqon Secures Funding to Accelerate Growth"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Note is fully subscribed, subject to customary conditions, by Ture Invest AB, a Stockholm based direct lender and alternative credit investor, and will be sought to be admitted to trading on the First North Bond Market of NASDAQ Copenhagen A/S.

Proceeds from the Note will be used to further develop the company’s recently launched cloud platform for life science researchers: XploreRNA™, and to accelerate growth by expanding the company’s  product offering within RNA analysis, in addition to general corporate purposes, including refinancing of current debt.

“This new financing will allow us to more rapidly capture the business potential of our XploreRNA™ cloud platform which holds the potential of becoming a leading e-commerce platform for researchers in our market. We now have funding to complete the company’s transition towards becoming the leading provider of customized solutions for RNA analysis by expanding our product offering for RNA analysis, including RNA sequencing,” said President and CEO, Dr. Lars Kongsbak.

Advertisement